Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials

Douxfils, Jonathan; Buckinx, Fanny; Mullier, François; Minet, Valentine; Rabenda, Véronique; Reginster, Jean‐Yves; Hainaut, Philippe; Bruyère, Olivier; Dogné, Jean‐Michel

doi:10.1161/jaha.113.000515

Public

Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials

Published in Journal of the American Heart Association • May 22, 2014

Authors:

Jonathan Douxfils

Fanny Buckinx

François Mullier

Abstract

BACKGROUND: Signals of an increased risk of myocardial infarction (MI) have been identified with dabigatran etexilate in randomized controlled trials (RCTs). METHODS AND RESULES: We conducted searches of the published literature and a clinical trials registry maintained by the drug manufacturer. Cri...

Subject

Medicine

Dabigatran

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!